Technology

PREDICTION BY

FOLLOW-UP

The prediction is conditional on the end of the war in Ukraine. As of mid-2026, the war has not clearly ended, so the condition has not been met, and the prediction cannot yet be evaluated.

PREDICTION BY

FOLLOW-UP

Incumbent big tech firms like Alphabet, Meta, and Microsoft aggressively integrated AI models into their products and services during 2024-2025, demonstrating a strong 'strike back' against AI upstarts, consistent with the metaphor.

PREDICTION BY

FOLLOW-UP

Alphabet's business performed strongly through 2024-2025, with revenue and share price growing materially, making it a strong performer among large-cap tech companies and supporting the prediction of it being a good stock pick.

PREDICTION BY

FOLLOW-UP

AI-enhanced chatbots and 'AI companions' have grown rapidly, and concerns about AI-enabled radicalization and deepfakes are documented. However, a widespread, clearly attributable wave of U.S. domestic terrorism 'from people in uniform weaponized by AI girlfriends' has not become a dominant threat. AI's net effect on job creation is also complex and not conclusively confirmed macroeconomically. The mechanism is plausible and partially visible, but the specific terrorism scenario has not fully materialized.

PREDICTION BY

FOLLOW-UP

GLP-1-based drugs saw massive uptake and media coverage in 2024–2025, with significant impacts on pharma revenues, consumer behavior, and expectations for obesity treatment. Measurable indicators suggest GLP-1 drugs had very substantial real-world impact, arguably more directly felt in everyday lives than GPT-4 for many people in 2024–2025, despite GPT-4's major influence in its own domain.

PREDICTION BY

FOLLOW-UP

AI investment, model releases, and corporate adoption continued to accelerate after 2024, especially in 2025-2026. Public search interest in 'AI' showed fluctuations but did not collapse. The claim that 2024 would represent 'Peak AI' has not been borne out, as AI activity and prominence have remained high or increased.

PREDICTION BY

FOLLOW-UP

Sandy Jordan claims this has happened and that a tool called G Translate is now being used in its place. This refers to a specific product or feature change within Google's translation offerings.

PREDICTION BY

FOLLOW-UP

GLP-1 weight-loss drugs became a major economic and societal storyline in 2024-2025, impacting health, consumer behavior, and equity markets. While AI models also had large impacts, GLP-1's effect on healthcare, consumer categories, and capital markets was arguably at least as visible, making the prediction directionally accurate.

PREDICTION BY

FOLLOW-UP

The media landscape is continually evolving with new technologies like AI maturing and reaching broader adoption, suggesting an ongoing 'inflection point' consistent with the prediction.

PREDICTION BY

FOLLOW-UP

Over 2024–2025, Alphabet’s stock delivered solid positive returns, supported by resilient search advertising, YouTube ad growth, and expanding cloud and AI offerings. While not the absolute top performer among all large-cap tech names, it was a reasonable and broadly successful call.

PREDICTION BY

FOLLOW-UP

GLP-1 drugs continued explosive growth in prescriptions and revenue through 2024-2025, with major CPG and food companies citing their impact on earnings calls. Media coverage frequently framed GLP-1 drugs as one of the most impactful technologies affecting health and consumer behavior.

PREDICTION BY

FOLLOW-UP

Alphabet proved to be a strong, defensible big-tech holding, though it did not unambiguously outperform all mega-cap peers in 2024–2025.

PREDICTION BY

FOLLOW-UP

Largely accurate in spirit: the bubble did not burst, but hype normalized and weaker AI stories deflated while core infrastructure and leading platforms remained strong.

PREDICTION BY

FOLLOW-UP

While AI has pressured lighter SaaS tools, a full 'apocalypse' has not materialized. Complex infrastructure, as Paparo predicted, remains essential.

PREDICTION BY

FOLLOW-UP

GLP-1 drugs have indeed shown explosive growth and broad economic effects, supporting the direction of high impact. However, the comparative claim of 'even more impact on the global economy this year than AI' is subjective and not cleanly verifiable with objective economic data. Both AI and GLP-1 are considered major economic drivers.

PREDICTION BY

FOLLOW-UP

GLP-1 drugs saw explosive adoption and major impact on consumer behavior and industries, as predicted. While AI also remained prominent, the significant impact of GLP-1 drugs in 2024 supports the \"year of GLP-1\" claim.

PREDICTION BY

FOLLOW-UP

It is too early to tell if AI's impact will overshadow those of mobile and the internet, as the prediction was made in 2025.

PREDICTION BY

FOLLOW-UP

GLP-1 drugs saw explosive growth and became a central theme in business and health coverage in 2024, influencing consumer behavior and industry discussions, consistent with Galloway's prediction of them being a defining 'tech of the year'.

PREDICTION BY

FOLLOW-UP

GLP-1 drugs saw explosive growth and became a central theme in business and health coverage in 2024, influencing consumer behavior and industry discussions, consistent with Galloway's prediction of them being a defining 'tech of the year.'

PREDICTION BY

FOLLOW-UP

Too early and too subjective to verify as true or false. Meta clearly became a leading consumer-scale AI deployer, but standing as *the* top AI company is a matter of perspective.

PREDICTION BY

FOLLOW-UP

GLP-1 drugs did become one of the most economically and culturally significant technologies in 2024, at least on par with mainstream AI coverage in business and consumer media.

PREDICTION BY

FOLLOW-UP

AI valuations had a mixed trajectory, peaking mid-2024 but rebounding later. Alphabet significantly advanced its AI integration and stock performance, leveraging its data.